Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Premium Content
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Janssen Biotech

Legend Biotech, a cell therapy subsidiary of Genscript Biotech, announced Tuesday that sales of its Carvykti cancer drug jumped 176% to $152 million in the third quarter from $55 million a year earlier.

FAST NEWS: Genscript’s new cancer drug sales surge in third quarter

The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday that sales of its Carvykti cancer drug jumped 176% to $152 million in the third quarter…
October 18, 2023
1548.HK LEGN.US
Legend Biotech announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration with Janssen Biotech.

FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses

The latest: Legend Biotech Corp. (LEGN.US) announced Tuesday its second quarter revenue jumped 513% year-on-year to $73.33 million, mainly due to higher revenue from the sale of Carvykti, a product in collaboration…
August 16, 2023
LEGN.US

FAST NEWS: Legend Biotech shares jump on rising cancer drug sales

The latest: Cell therapy company Legend Biotech Corp. (LEGN.US) recorded net sales of $117 million in the second quarter for its Carvykti cancer drug, up 65% from the previous quarter, according to…
July 21, 2023
LEGN.US

FAST NEWS: Legend Biotech to raise $300 million from share sale

The latest: Genscript Biotech Corp. (1548.HK) announced Monday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) will sell about 5.5 million new American Depositary Shares (ADSs) to an entity advised by…
May 8, 2023
LEGN.US 1548.HK

FAST NEWS: Legend Biotech cancer drug posts strong first-quarter sales

The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), announced Tuesday it recorded net sales of approximately $72 million in the first quarter for its Carvykti cancer…
April 19, 2023
LEGN.US

FAST NEWS: Legend Biotech Pares Losses on Milestone Revenue

The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), reported a loss of $41.09 million in the first quarter, half the $80.9 million loss from the same…
June 2, 2022

Recent Articles

Legend Biotech, a cell therapy subsidiary of Genscript Biotech, announced Tuesday that sales of its Carvykti cancer drug jumped 176% to $152 million in the third quarter from $55 million a year earlier.
October 18, 2023

FAST NEWS: Genscript’s new cancer drug sales surge in third quarter

1548.HK LEGN.US
August 16, 2023

FAST NEWS: Legend Biotech’s revenue soars, but fails to turnaround losses

LEGN.US
July 21, 2023

FAST NEWS: Legend Biotech shares jump on rising cancer drug sales

LEGN.US
May 8, 2023

FAST NEWS: Legend Biotech to raise $300 million from share sale

LEGN.US 1548.HK
April 19, 2023

FAST NEWS: Legend Biotech cancer drug posts strong first-quarter sales

LEGN.US
June 2, 2022

FAST NEWS: Legend Biotech Pares Losses on Milestone Revenue

RELATED ARTICLES

  1. Henlius Bio
    February 6, 2025
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  2. January 9, 2025
    Cancer drug maker Genfleet joins Hong Kong IPO influx
  3. March 27, 2025
    CARsgen seeks cell therapy breakthrough but stays in the red for now
    2171.HK
  4. March 20, 2025
    A blockbuster cancer drug? TYK’s claims go under the microscope
    2410.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Premium Content
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2024 Bamboo Works. All rights reserved.